🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Suzetrigine in Total Hip Arthroplasty

RecruitingPhase 3Ages 18 Years - 80 YearsAllHospital for Special Surgery, New York
NCT07226700 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcom

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients undergoing primary THA (posterior approach) with participating surgeons * Age 18 to 80 years old * Planned discharge to home * Planned use of neuraxial anesthesia * American Society of Anesthesiologists (ASA) Physical Status 1 - 3 Exclusion Criteria: * ASA greater than 3 * Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery) * History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator) * History of QT prolongation * Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device * Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse * Inability to comply with any component of the study protocol * Younger than 18 or greater than 80 years old at the time of enrollment * Patient already on Suzetrigine * Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease/Child Pugh B or C, use of strong CYP3 inhibitors or inducers) * Contraindications to neuraxial anesthesia or any other part of the study protocol * Participation in another investigational drug or device study * Pregnancy
💊

What it tests

  • Suzetrigine
  • Placebo
📍

Where

1 site
Hospital for Special Surgery
New York, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy